OKYO Pharma is a clinical-stage biopharmaceutical company uniquely positioned to address Neuropathic Corneal Pain (NCP), a debilitating ocular condition with a massive unmet medical need and no FDA-approved therapies. The company's lead asset, urcosimod (formerly OK-101), is a first-in-class lipid-conjugated chemerin peptide agonist targeting the ChemR23 receptor. Urcosimod has demonstrated highly encouraging Phase 2a proof-of-concept results, showing a dramatic and clinically meaningful reduction in pain severity (5.5-point mean improvement on a 10-point VAS scale vs. 2.75 for placebo) with an excellent safety profile. Backed by FDA alignment on a Phase 2b/3 trial design and Fast Track designation, OKYO is poised to initiate a pivotal 150-patient trial in 1H 2026. While the company operates with typical early-stage biotech risks—including pre-revenue status, ongoing losses, and reliance on equity financing—its asset-light virtual model and recent $20 million capital raise provide the necessary runway to reach critical clinical milestones, offering a high-risk, high-reward opportunity for biotechnology investors.